<DOC>
	<DOCNO>NCT01604252</DOCNO>
	<brief_summary>This multi-center , prospective , observational cohort study evaluate effectiveness , safety utilization treatment patient advance basal cell carcinoma basal cell carcinoma nevus syndrome . The total study duration anticipate maximum 8 year , include 3 year patient recruitment 5 year follow-up .</brief_summary>
	<brief_title>An Observational Study Treatment Patterns Effectiveness Safety Outcomes Advanced Basal Cell Carcinoma Basal Cell Carcinoma Nevus Syndrome Patients ( RegiSONIC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Patients basal cell carcinoma ( BCC ) meet either follow definition : Patients determine advanced disease ( aBCC ) within 90 day prior study enrollment , diagnose basal cell carcinoma nevus syndrome ( BCCNS ) treat investigational approved hedgehog pathway inhibitor Patients aBCC diagnose BCCNS previously treat vismodegib part Genentech study SHH4476g , SHH4437g , SHH4811g ( EAP ) Patients BCCNS either aBCC multiple BCCs stage define protocol ( may include patient previously enrol Genentech study SHH4476g , SHH4437g , SHH4811g ( EAP ) ) Participation clinical trial within 90 day prior study enrollment either involved treatment aBCC involve treatment investigational approve hedgehog pathway inhibitor , except patient treat vismodegib part Genentech study SHH4476g , SHH4437g , SHH4811g ( EAP )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>